Literature DB >> 19641203

Protection against a malaria challenge by sporozoite inoculation.

Meta Roestenberg1, Matthew McCall, Joost Hopman, Jorien Wiersma, Adrian J F Luty, Geert Jan van Gemert, Marga van de Vegte-Bolmer, Ben van Schaijk, Karina Teelen, Theo Arens, Lopke Spaarman, Quirijn de Mast, Will Roeffen, Georges Snounou, Laurent Rénia, Andre van der Ven, Cornelus C Hermsen, Robert Sauerwein.   

Abstract

BACKGROUND: An effective vaccine for malaria is urgently needed. Naturally acquired immunity to malaria develops slowly, and induction of protection in humans can be achieved artificially by the inoculation of radiation-attenuated sporozoites by means of more than 1000 infective mosquito bites.
METHODS: We exposed 15 healthy volunteers--with 10 assigned to a vaccine group and 5 assigned to a control group--to bites of mosquitoes once a month for 3 months while they were receiving a prophylactic regimen of chloroquine. The vaccine group was exposed to mosquitoes that were infected with Plasmodium falciparum, and the control group was exposed to mosquitoes that were not infected with the malaria parasite. One month after the discontinuation of chloroquine, protection was assessed by homologous challenge with five mosquitoes infected with P. falciparum. We assessed humoral and cellular responses before vaccination and before the challenge to investigate correlates of protection.
RESULTS: All 10 subjects in the vaccine group were protected against a malaria challenge with the infected mosquitoes. In contrast, patent parasitemia (i.e., parasites found in the blood on microscopical examination) developed in all five control subjects. Adverse events were mainly reported by vaccinees after the first immunization and by control subjects after the challenge; no serious adverse events occurred. In this model, we identified the induction of parasite-specific pluripotent effector memory T cells producing interferon-gamma, tumor necrosis factor alpha, and interleukin-2 as a promising immunologic marker of protection.
CONCLUSIONS: Protection against a homologous malaria challenge can be induced by the inoculation of intact sporozoites. (ClinicalTrials.gov number, NCT00442377.) 2009 Massachusetts Medical Society

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19641203     DOI: 10.1056/NEJMoa0805832

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  277 in total

Review 1.  Controlled human blood stage malaria infection: current status and potential applications.

Authors:  Christopher J A Duncan; Simon J Draper
Journal:  Am J Trop Med Hyg       Date:  2012-04       Impact factor: 2.345

Review 2.  Blood stage vaccines for Plasmodium falciparum: current status and the way forward.

Authors:  Ruth D Ellis; Issaka Sagara; Ogobara Doumbo; Yimin Wu
Journal:  Hum Vaccin       Date:  2010-08

Review 3.  The apicoplast.

Authors:  Geoffrey Ian McFadden
Journal:  Protoplasma       Date:  2010-12-17       Impact factor: 3.356

4.  Strain-specific immunity induced by immunization with pre-erythrocytic stages of Plasmodium chabaudi.

Authors:  R L Culleton; M Inoue; S E Reece; S Cheesman; R Carter
Journal:  Parasite Immunol       Date:  2011-01       Impact factor: 2.280

5.  CD8 T cell independent immunity after single dose infection-treatment-vaccination (ITV) against Plasmodium yoelii.

Authors:  Katherine L Doll; Noah S Butler; John T Harty
Journal:  Vaccine       Date:  2013-12-07       Impact factor: 3.641

Review 6.  Immune mechanisms in malaria: new insights in vaccine development.

Authors:  Eleanor M Riley; V Ann Stewart
Journal:  Nat Med       Date:  2013-02       Impact factor: 53.440

Review 7.  Chemical Attenuation in the Development of a Whole-Organism Malaria Vaccine.

Authors:  Amber I Raja; Danielle I Stanisic; Michael F Good
Journal:  Infect Immun       Date:  2017-06-20       Impact factor: 3.441

Review 8.  Live attenuated pre-erythrocytic malaria vaccines.

Authors:  Gladys J Keitany; Marissa Vignali; Ruobing Wang
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

9.  Advances and challenges in malaria vaccine development.

Authors:  Ruobing Wang; Joseph D Smith; Stefan H I Kappe
Journal:  Expert Rev Mol Med       Date:  2009-12-16       Impact factor: 5.600

10.  A Recombinant Chimeric Ad5/3 Vector Expressing a Multistage Plasmodium Antigen Induces Protective Immunity in Mice Using Heterologous Prime-Boost Immunization Regimens.

Authors:  Monica Cabrera-Mora; Jairo Andres Fonseca; Balwan Singh; Chunxia Zhao; Natalia Makarova; Igor Dmitriev; David T Curiel; Jerry Blackwell; Alberto Moreno
Journal:  J Immunol       Date:  2016-08-29       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.